Quick Answer
Lineage Cell Therapeutics, Inc. reported Gross Profit of $8.27 million for fiscal year 2023.
Lineage Cell Therapeutics, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2023 | $8.27M | -40.8% |
| 2022 | $13.97M | +379.4% |
| 2021 | $2.92M | +102.3% |
| 2020 | $1.44M | -53.6% |
| 2019 | $3.10M | -33.8% |
| 2018 | $4.69M | +42.4% |
| 2017 | $3.29M | -40.9% |
| 2016 | $5.57M | -6.1% |
| 2015 | $5.93M | +34.5% |
| 2014 | $4.41M | +21.0% |
| 2013 | $3.64M | +4.6% |
| 2012 | $3.48M | -20.1% |
| 2011 | $4.35M | +18.3% |
| 2010 | $3.68M | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $1.08M | -61.0% | -65.2% |
| June 30, 2023 | $3.10M | -28.6% | +36.7% |
| March 31, 2023 | $2.27M | -55.2% | -18.0% |
| September 30, 2022 | $2.76M | +115.0% | -36.3% |
| June 30, 2022 | $4.34M | +1020.9% | -14.3% |
| March 31, 2022 | $5.06M | +1714.0% | +293.9% |
| September 30, 2021 | $1.28M | +174.0% | +232.0% |
| June 30, 2021 | $387.0K | +24.4% | +38.7% |
- Lineage Cell Therapeutics, Inc. showed a decrease of -40.8% in Gross Profit compared to the prior fiscal year.
- Over the 2010–2023 period, Lineage Cell Therapeutics, Inc.’s gross profit has grown by 124.8% (from $3.68 million to $8.27 million).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 7, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: